Dornase alfa

Drug Profile

Dornase alfa

Alternative Names: DNase; Dornase alpha; dornase-alpha; Pulmozyme; Recombinant human deoxyribonuclease I; rhDNase

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; University of Illinois at Chicago
  • Class Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase I/II Dry eyes; Graft-versus-host disease
  • Discontinued Chronic obstructive pulmonary disease; Lupus nephritis

Most Recent Events

  • 06 Feb 2017 Dornase alfa is still in phase I/II trials for Dry eyes in USA (Ophthalmic, drops)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Jul 2014 Phase-I/II clinical trials in Dry eyes in USA (Ophthalmic, drops) (NCT02193490)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top